Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistent reflux symptoms cause anxiety, depression, and mental health and sleep disorders in gastroesophageal reflux disease patients.
Kimura Y, Kamiya T, Senoo K, Tsuchida K, Hirano A, Kojima H, Yamashita H, Yamakawa Y, Nishigaki N, Ozeki T, Endo M, Nakanishi K, Sando M, Inagaki Y, Shikano M, Mizoshita T, Kubota E, Tanida S, Kataoka H, Katsumi K, Joh T. Kimura Y, et al. J Clin Biochem Nutr. 2016 Jul;59(1):71-7. doi: 10.3164/jcbn.16-9. Epub 2016 May 21. J Clin Biochem Nutr. 2016. PMID: 27499583 Free PMC article.
Coexpression of organic anion-transporting polypeptides 1B3 and multidrug-resistant proteins 2 increases the enhancement effect of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on hepatocellular carcinoma in magnetic resonance imaging.
Kimura Y, Sato S, Hitomi E, Ohyama M, Adachi K, Inagaki Y, Yamakawa Y, Hirano A, Kawai H, Tsuchida K, Senoo K, Katsumi K, Joh T. Kimura Y, et al. Hepatol Res. 2014 Mar;44(3):327-37. doi: 10.1111/hepr.12128. Epub 2013 May 7. Hepatol Res. 2014. PMID: 23607695
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment.
Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y, Yamada T, Tsukamoto H, Mizushima T, Sugimura N, Katano T, Tanida S, Kataoka H, Sasaki M. Suzuki T, et al. Among authors: kimura y. Case Rep Gastroenterol. 2019 Feb 6;13(1):37-49. doi: 10.1159/000496453. eCollection 2019 Jan-Apr. Case Rep Gastroenterol. 2019. PMID: 31182942 Free PMC article.
Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
Mori Y, Kataoka H, Ebi M, Adachi K, Yamaguchi Y, Hayashi N, Hirata Y, Sobue S, Ishihara R, Suzuki Y, Mizushima T, Inoue Y, Hasegawa I, Ono S, Hirano A, Kimura Y, Seno K, Ozeki K, Shimura T, Kubota E. Mori Y, et al. Among authors: kimura y. J Gastrointest Cancer. 2022 Dec;53(4):930-938. doi: 10.1007/s12029-021-00711-0. Epub 2021 Sep 22. J Gastrointest Cancer. 2022. PMID: 34550548 Clinical Trial.
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Matoya S, et al. Among authors: kimura y. Hepatol Res. 2023 Jun;53(6):511-521. doi: 10.1111/hepr.13886. Epub 2023 Feb 18. Hepatol Res. 2023. PMID: 36723964
6,034 results